xoma corporate presentation

English (USA)

English (UK)

English (Canada)

English (India)

Deutsch (Deutschland)

Deutsch (Österreich)

Deutsch (Schweiz)

Français (France)

Français (Suisse)

Nederlands (Nederland)

Nederlands (België)

• Top Capitalization
• United States
• North America
• Middle East
• Sector Research
• Earnings Calendar
• Equities Analysis
• Most popular
• TESLA, INC.
• NIPPON ACTIVE VALUE FUND PLC
• THE EDINBURGH INVESTMENT TRUST PLC
• BLACKSTONE INC.
• NETFLIX, INC.
• NVIDIA CORPORATION
• Index Analysis
• Indexes News
• EURO STOXX 50
• Currency Cross Rate
• Currency Converter
• Forex Analysis
• Currencies News
• Precious metals
• Agriculture
• Industrial Metals
• Livestock and Cattle
• CRUDE OIL (WTI)
• CRUDE OIL (BRENT)

• Developed Nations
• Emerging Countries
• South America
• Analyst Reco.
• Capital Markets Transactions
• New Contracts
• Profit Warnings
• Appointments
• Press Releases
• Security Transactions
• Earnings reports
• New markets
• New products
• Corporate strategies
• Legal risks
• Share buybacks
• Mergers and acquisitions
• Call Transcripts
• Currency / Forex
• Commodities
• Cryptocurrencies
• Interest Rates
• Asset Management
• Climate and ESG
• Cybersecurity
• Geopolitics
• Central Banks
• Private Equity
• Business Leaders
• All our articles
• Most Read News
• All Analysis
• Satirical Cartoon
• Today's Editorial
• Crypto Recap
• Behind the numbers
• All our investments
• Asia, Pacific
• Virtual Portfolios
• USA Portfolio
• European Portfolio
• Asian Portfolio
• My previous session
• My most visited
• Undervalued stocks
• Trend-Following Stocks
• Growth stocks
• Yield stocks
• Financial Data
• Ageing Population
• The Vegan Market
• Let's all cycle!
• Unusual volumes
• New Historical Highs
• New Historical Lows
• Top Fundamentals
• Sales growth
• Earnings Growth
• Profitability
• Rankings Valuation
• Enterprise value
• Top Consensus
• Analyst Opinion
• Target price
• Estimates Revisions
• Top ranking ESG
• Environment
• Visibility Ranking
• Stock Screener Home
• Quantum computing
• Artificial Intelligence
• Solar energy
• Oversold stocks
• Overbought stocks
• Close to resistance
• Close to support
• Accumulation Phases
• Most volatile stocks
• Top Investor Rating
• Top Trading Rating
• Top Dividends
• Low valuations
• All my stocks
• Stock Screener
• Stock Screener PRO
• Portfolio Creator
• Event Screener
• Dynamic Chart
• Economic Calendar
• ProRealTime Trading
• Our subscriptions
• Our Stock Picks
• Thematic Investment Lists

XOMA Corporation

Us98419j2069, biotechnology & medical research.

• XOMA to Present at Upcoming Investor Conferences in March

EMERYVILLE, Calif. , Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following March 2024 investor conferences:

• The Leerink Partners 2024 Global Biopharma Conference , which is being held March 11-13, 2024 , in Miami, FL.  Mr. Hughes will present the corporate overview on Monday, March 11, 2024 , at 10:40 AM ET .  The presentation can be accessed at https://bit.ly/3SxDK0E .

XOMA’s presentations can also be accessed by visiting the investor relations section of the Company’s website at www.xoma.com.  A replay of each presentation will be available and archived on the site for 90 days after the event.

About XOMA Corporation XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about the Company and its portfolio, please visit www.xoma.com.

2024 GlobeNewswire, Inc., source Press Releases

Latest news about XOMA Corporation

Chart xoma corporation.

Company Profile

Income statement evolution, ratings for xoma corporation, analysts' consensus, eps revisions, quarterly earnings - rate of surprise, sector bio therapeutic drugs.

• Stock Market
• News XOMA Corporation

Presentations made painless

• Get Premium

XOMA: Business Model, SWOT Analysis, and Competitors 2024

Inside This Article

In this comprehensive exploration, we delve into the intricacies of XOMA's business model, providing a clear understanding of its strategic operations and revenue generation mechanisms as of 2024. We further enhance our analysis by conducting a detailed SWOT (Strengths, Weaknesses, Opportunities, and Threats) analysis, offering insights into XOMA's internal and external environment. Additionally, we compare XOMA with its competitors, identifying key differentiators and market positions. This article aims to present a holistic view of XOMA's standing in the biotechnology sector, highlighting its potential for growth and areas of vulnerability.

What You Will Learn

Ownership and Strategic Vision of XOMA: Discover who owns XOMA and the driving mission statement that guides the company's direction and strategic decisions.

Revenue Generation and Business Model Insights: Understand how XOMA makes money through an in-depth explanation of its Business Model Canvas, providing insight into its operations, revenue streams, and value proposition.

Competitive Landscape and Strategic Positioning: Learn about XOMA's main competitors in the biotech industry and gain insights from a detailed SWOT analysis, highlighting the company's strengths, weaknesses, opportunities, and threats in the market.

Who owns XOMA?

Understanding the ownership structure of any company is crucial for investors, as it can give insights into the company's strategic direction, financial health, and potential for growth or risk. XOMA Corporation, a biotechnology company known for its innovative approaches in the development of therapeutic antibodies, is no exception. This section explores the intricate details of who owns XOMA, shedding light on the major stakeholders and their possible influence on the company's operations and future.

Institutional Investors

The backbone of XOMA's ownership structure is its institutional investors. These entities include mutual funds, pension funds, endowments, and other large organizations that invest in the stock market. For XOMA, institutional investors represent a significant portion of its shares, indicating a strong level of confidence in the company's future prospects. Their involvement is crucial as they bring in substantial capital, expertise, and stability to the company's shareholder base.

Retail Investors

Alongside institutional investors, retail investors — individual shareholders who buy and sell securities for their personal accounts — also play a role in XOMA's ownership. While they might not wield as much financial power individually as institutional investors, collectively, they contribute to the company's liquidity and market presence. The enthusiasm and support of retail investors can be a driving force in the market performance of a company's shares.

Insider Ownership

Insiders, including senior executives, board members, and other key employees, often own a portion of the company's shares. This insider ownership is closely watched by investors as it can signal confidence in the company's future. If insiders hold a substantial amount of shares, it is often interpreted as a positive sign that those with the most intimate knowledge of the company believe in its growth and success. For XOMA, examining the extent and changes in insider ownership can provide valuable clues about its internal confidence levels and future direction.

Public vs Private Ownership

XOMA is a publicly traded company, meaning its shares are available for purchase on the open market to anyone interested in owning a piece of the company. This public ownership structure contrasts with private companies, which are owned by a smaller number of investors that often includes the company's founders, their families, and perhaps a handful of outside investors. The public nature of XOMA allows for greater transparency and liquidity but also subjects the company to the ebbs and flows of market sentiment and regulatory scrutiny.

The ownership structure of XOMA is a dynamic mix of institutional and retail investors, along with insiders who have a direct stake in the company's success. This mix not only reflects the diverse interest in XOMA's promising biotechnology endeavors but also influences the company's strategic decisions and its responsiveness to market changes. For investors considering XOMA, understanding this ownership landscape is essential for making informed decisions about the potential risks and rewards of becoming part of the XOMA shareholder community.

What is the mission statement of XOMA?

XOMA Corporation, a name synonymous with innovation and pioneering in the biotechnology sector, operates with a clear and forward-looking mission statement that serves as its north star. The essence of XOMA's mission is to leverage its proprietary antibody technologies to discover and develop innovative therapeutics that can address significant unmet medical needs.

At its core, XOMA is dedicated to improving the lives of patients around the globe. The company's mission reflects a commitment not only to scientific excellence and innovation but also to the practical application of its research to produce treatments that can make a real difference in people's lives. This dual focus ensures that XOMA's efforts are always aligned with the ultimate goal of enhancing healthcare outcomes and providing solutions where there are gaps in current medical treatments.

Moreover, XOMA places a strong emphasis on collaboration and partnership within the scientific and medical communities. The company believes that by working together, leveraging diverse expertise and resources, it can accelerate the development of groundbreaking therapeutics. This collaborative spirit is an integral part of XOMA's mission, underpinning its approach to research and development and ensuring that the company remains at the forefront of biotechnological advancements.

In summary, XOMA's mission statement encapsulates its dedication to scientific innovation, patient welfare, and collaborative progress in the biotech field. Through its steadfast commitment to this mission, XOMA continues to push the boundaries of what is possible in medicine, aiming to deliver transformative treatments that can significantly improve patient outcomes.

How does XOMA make money?

XOMA Corporation, a pioneer in the discovery and development of therapeutic antibodies, has established a unique business model that differentiates it from typical biopharmaceutical companies. Unlike many of its peers, XOMA's revenue generation strategy is not solely reliant on the commercial sales of its own drug products. Instead, the company has carved out a niche for itself by leveraging its extensive portfolio of patented antibody technologies and expertise in drug development. The primary avenues through which XOMA generates income include licensing agreements, milestone payments, and royalties. Below, we delve into each of these revenue streams to understand how XOMA capitalizes on its scientific assets and expertise.

Licensing Agreements

One of XOMA's key strategies for revenue generation is through entering into licensing agreements with other pharmaceutical and biotechnology companies. These agreements grant the licensee the rights to use XOMA's proprietary antibody technologies and candidates for their own research, development, and commercialization efforts. In return, XOMA receives upfront payments, which are recognized at the start of the agreement. These licensing deals can be quite lucrative and provide a steady inflow of capital to fund XOMA's ongoing research and operational costs.

Milestone Payments

In addition to upfront payments from licensing agreements, XOMA often negotiates milestone payments. These are contingent upon the licensee achieving specific developmental, regulatory, or commercial milestones with the licensed antibody technologies or drug candidates. For example, XOMA may receive a payment when a drug candidate successfully completes a phase of clinical trials or obtains regulatory approval in a major market. Milestone payments can vary significantly in amount, depending on the terms of each agreement and the success of the licensed products. They represent an important component of XOMA's revenue model, incentivizing the company to support its partners in advancing the development of licensed products.

Royalties form the third pillar of XOMA's revenue-generating strategy. Under the terms of most licensing agreements, XOMA is entitled to receive a percentage of the net sales of any commercialized products that utilize its antibody technologies or drug candidates. These royalty rates typically range from low single digits to mid-teens percentage of sales, depending on the specific agreement and product. As products progress through development and onto the market, royalty revenues can provide a long-term, sustainable income source for XOMA. This revenue stream is particularly valuable as it is directly tied to the commercial success of the licensed products, potentially leading to significant financial returns without the burden of commercialization costs.

In conclusion, XOMA has adeptly positioned itself in the biopharmaceutical industry by focusing on monetizing its proprietary antibody technologies and drug development expertise through licensing agreements, milestone payments, and royalties. This innovative approach allows XOMA to generate revenue while minimizing the risks and costs associated with the drug development process. As the company continues to expand its portfolio and enter into new agreements, its ability to generate income through these avenues is likely to grow, offering a promising outlook for its financial health and future success.

XOMA Business Model Canvas Explained

The XOMA Corporation, a leader in the discovery and development of therapeutic antibodies, has developed a robust business model that enables it to navigate the complex landscape of biotechnology and pharmaceuticals. By dissecting the XOMA business model canvas, we can gain insights into the strategic decisions that drive the company's success.

Key Partnerships

XOMA's business model is heavily reliant on forming strategic partnerships with larger pharmaceutical companies and research institutions. These partnerships are crucial for several reasons. Firstly, they provide XOMA with the necessary funding to advance its research and development efforts without bearing the full financial risk. Secondly, these collaborations offer access to a wider range of expertise and technologies, accelerating the development process. Lastly, partnerships with established pharmaceutical companies facilitate the commercialization and distribution of XOMA's products, leveraging the partners' extensive networks and market presence.

Value Propositions

XOMA's value proposition centers around its proprietary platform technologies and a deep pipeline of antibody candidates. The company specializes in the discovery and development of monoclonal antibodies, a class of highly targeted therapeutics that can be used in the treatment of a wide variety of diseases, including cancer, autoimmune disorders, and infectious diseases. XOMA's ability to generate novel antibody therapies with improved efficacy and safety profiles distinguishes it from competitors and offers significant value to its partners and patients.

Customer Segments

XOMA's customer segments are twofold. The primary customers are the pharmaceutical and biotechnology companies that license XOMA's technologies or engage in collaborative research and development projects. These entities seek to expand their own pipelines with innovative therapeutics. The secondary customer segment comprises the patients who ultimately benefit from XOMA's products. While these patients do not directly contribute to XOMA's revenue, their needs and outcomes are central to the company's mission and indirectly influence its business success through regulatory approvals and market adoption of its therapies.

Revenue Streams

The company's revenue streams are diversified across licensing fees, milestone payments, and royalties on product sales. Licensing fees are generated when a partner company gains access to XOMA's proprietary technologies or therapeutic candidates. Milestone payments are received upon achieving specific development, regulatory, or commercial milestones within these partnerships. Royalties are then earned on the sales of products developed using XOMA's technologies, providing a sustained income stream that can support the company's long-term growth and R&D investment.

Key Activities

XOMA's key activities include research and development, particularly in antibody engineering and discovery. The company invests heavily in its R&D efforts to maintain a competitive edge and advance its pipeline of therapeutic candidates. Additionally, XOMA engages in business development activities to identify and secure strategic partnerships, which are essential for funding and commercializing its innovations.

Key Resources

The company's key resources are its proprietary technology platforms, intellectual property portfolio, and scientific expertise. XOMA's platforms enable the rapid identification and optimization of antibody candidates, which is a critical capability in the fast-paced biotech industry. Its intellectual property protects these innovations, while the expertise of its scientific team ensures the continued advancement of its research and development efforts.

Cost Structure

XOMA's cost structure is primarily dominated by research and development expenses. These costs include salaries for scientific personnel, laboratory supplies, and the expenses associated with conducting preclinical and clinical trials. Despite the significant investment required for R&D, XOMA's strategic partnerships help to offset these expenses through upfront payments, milestone achievements, and royalties.

XOMA utilizes a variety of channels to engage with its partners and stakeholders. Direct sales and business development teams are key for initiating and maintaining partnerships. Moreover, the company leverages scientific conferences, publications, and digital platforms to showcase its research findings and technological capabilities, attracting interest from potential partners and the broader scientific community.

Customer Relationships

XOMA maintains its customer relationships through continuous engagement and collaboration with its partners. The company works closely with its pharmaceutical and biotech partners throughout the development process, ensuring that projects remain on track and that any challenges are addressed collaboratively. By fostering strong, long-term relationships, XOMA ensures the ongoing success of its partnerships and the commercial viability of its therapeutic candidates.

By examining the XOMA business model canvas, it's clear that the company's strategy is finely tuned to the unique demands of the biotech industry. Through strategic partnerships, a strong value proposition, and a focus on innovation, XOMA is well-positioned to continue its trajectory of growth and success in the development of novel antibody therapies.

Which companies are the competitors of XOMA?

XOMA Corporation, a biotechnology company, operates in a highly competitive industry that is driven by innovation, research, and development. The company, focusing on the discovery and development of monoclonal antibody-based therapeutics, faces competition from a range of companies, from large pharmaceutical firms to smaller biotech entities. Here are some of the notable competitors of XOMA:

1. Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals is a leading biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. With a strong focus on monoclonal antibodies, similar to XOMA, Regeneron is well-known for its innovative treatments in areas such as ophthalmology, inflammatory and autoimmune diseases, and oncology, making it a direct competitor in the biopharmaceutical space.

2. Amgen Inc.

Amgen is one of the world's largest independent biotechnology companies, with a broad portfolio of products and a significant investment in research and development. Amgen's focus areas include oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology, and neuroscience. Their commitment to developing high-quality biologic treatments positions them as a formidable competitor to XOMA.

3. Genmab A/S

Based in Denmark, Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Their proprietary technology platforms and innovative approach to antibody creation make them a key player in the field and a competitor to XOMA, particularly in the oncology segment.

4. Biogen Inc.

Biogen is a global biopharmaceutical company that develops, markets, and manufactures therapies for people living with serious neurological diseases as well as rare conditions. Biogen's emphasis on advanced biologic treatments, including monoclonal antibodies for multiple sclerosis and other autoimmune disorders, places it in direct competition with XOMA's therapeutic development efforts.

5. Roche Holding AG

Roche is a global pioneer in pharmaceuticals and diagnostics and is the world's largest biotech company. With its strong focus on medical research and diagnostics, Roche develops innovative drugs and devices across multiple therapeutic areas, including oncology, immunology, infectious diseases, ophthalmology, and neuroscience. Roche's extensive portfolio and its investments in monoclonal antibody technologies make it a significant competitor to XOMA.

These companies represent just a fraction of the competitive landscape faced by XOMA. The biotechnology and pharmaceutical sectors are characterized by rapid innovation and a continuous influx of new players, making it a challenging environment for any company. However, this competition also drives progress in medical research and the development of new therapies, ultimately benefiting patients worldwide.

XOMA SWOT Analysis

In the ever-evolving biotechnology sector, XOMA Corporation stands out as a unique entity primarily focused on the discovery and development of therapeutic antibodies. A SWOT analysis—an examination of strengths, weaknesses, opportunities, and threats—provides a comprehensive insight into XOMA's current position within the industry and its potential future trajectory. Let's delve deeper into the SWOT analysis of XOMA to understand its strategic position better.

• Innovative Product Pipeline : XOMA boasts a diversified and innovative product pipeline with a focus on monoclonal antibodies, which are at the forefront of biotechnological advancements. This positions the company well in a market that values cutting-edge treatments.
• Royalty Agreements : A unique strength of XOMA is its royalty agreement strategy. The company has successfully negotiated multiple royalty agreements for its developed antibodies, ensuring a steady income stream without the burden of manufacturing and marketing costs.
• Strong Intellectual Property Portfolio : XOMA has built a robust portfolio of patents that protect its innovations, ensuring long-term competitiveness and the ability to negotiate favorable partnership terms.
• Dependence on Partnerships : XOMA's business model heavily relies on partnerships for the development and commercialization of its products. This can lead to vulnerabilities if a partner fails to meet its obligations or if strategic interests diverge.
• Limited Manufacturing Capability : As a company focused on research and development, XOMA lacks extensive manufacturing capabilities. This limitation could pose challenges in rapidly scaling up production for high-demand products.
• Financial Constraints : Despite the income from royalty agreements, XOMA faces financial challenges typical of biotech firms in the R&D phase, including fluctuating revenues and the need for continuous investment in new projects.
• Opportunities
• Expansion of Antibody Therapeutics : The growing demand for antibody therapeutics offers XOMA significant opportunities for expansion and collaboration. Advances in technology and increased investment in healthcare post-pandemic are driving this trend.
• Strategic Partnerships and Acquisitions : By entering into strategic partnerships or acquiring complementary businesses, XOMA can leverage external expertise and resources to accelerate product development and market penetration.
• Global Market Penetration : Expanding into emerging markets could significantly increase XOMA's revenue streams. These regions are experiencing rapid growth in healthcare spending, presenting a lucrative opportunity for XOMA's innovative treatments.
• Intense Competition : The biotechnology industry is highly competitive, with many companies working on similar treatments. XOMA must continuously innovate to maintain its competitive edge.
• Regulatory Challenges : The complex regulatory environment for pharmaceuticals can delay product approvals and increase development costs, impacting XOMA's ability to bring new treatments to market quickly.
• Market Volatility : Economic downturns and fluctuations in healthcare spending can affect XOMA's financial performance. Additionally, changes in patent laws and healthcare policies pose risks to the company's revenue model.

In conclusion, XOMA Corporation is positioned at a strategic juncture with its innovative approach to antibody therapeutics and a strong emphasis on royalty income. However, to navigate its weaknesses and threats successfully, the company must leverage its strengths and opportunities, focusing on strategic partnerships, market expansion, and continuous innovation.

Key Takeaways from XOMA Overview

Ownership of XOMA : XOMA Corporation is a publicly traded company, meaning its ownership is distributed among individual and institutional shareholders who purchase shares on the stock market. The largest shareholders often include investment funds, hedge funds, and major financial institutions, alongside retail investors.

Mission Statement : XOMA's mission revolves around leveraging its proprietary antibody discovery and development platform to pioneer innovative therapies for patients with diseases that have limited treatment options. The company focuses on rare diseases and immunological conditions, aiming to transform cutting-edge scientific research into impactful medicines.

Revenue Generation : XOMA primarily makes money through licensing agreements, partnerships, and royalties. The company capitalizes on its antibody expertise by partnering with larger pharmaceutical companies, offering them access to its technology and research in exchange for upfront payments, milestone payments, and royalties on sales of marketed products developed from its platform.

Business Model Canvas : The XOMA Business Model Canvas highlights the company's value proposition in offering high-value, low-risk development opportunities to the biopharmaceutical industry through its novel antibody technology and licensing strategy. Key partners include biotech giants and research institutions, while key resources are its proprietary technologies and experienced research team. Its customer segments are largely other biopharma companies looking for innovative drug candidates.

Competition and SWOT Analysis : XOMA faces competition from both direct antibody therapy developers and broader biopharmaceutical firms. Competitors include companies like Regeneron, Amgen, and Genmab. In its SWOT analysis, strengths include a strong patent portfolio and a risk-mitigated business model; weaknesses might involve reliance on partner success and the competitive landscape. Opportunities for XOMA include expanding its licensing model and exploring new therapeutic areas, while threats could come from regulatory challenges and intense competition in the biopharma sector.

In conclusion, XOMA Corporation, a publicly traded biotechnology company, presents a unique profile in the competitive landscape of biopharmaceuticals. The ownership of XOMA is distributed among institutional investors, private equity firms, and individual stakeholders, reflecting a broad base of confidence in the company's potential.

XOMA's mission statement emphasizes its commitment to leveraging its proprietary antibody expertise to transform the lives of patients with rare diseases. This focus is not only noble but strategic, targeting a niche yet crucial segment of the healthcare market.

The company's revenue model is multifaceted, primarily revolving around licensing agreements, partnerships for drug development, and royalties from successfully commercialized therapies. By capitalizing on its innovative antibody discovery and development platform, XOMA has established a sustainable business model, as detailed in the XOMA Business Model Canvas. This framework highlights the company's value propositions, key activities, customer relationships, and revenue streams, among other critical business aspects.

In the competitive arena, XOMA faces challenges and opportunities. Competitors include a range of biotech firms focused on antibody technologies and rare disease therapies. Despite this, XOMA distinguishes itself through its specialized focus and strategic partnerships.

The SWOT analysis of XOMA underscores its strengths, such as a strong patent portfolio and expertise in antibody development, while also noting challenges such as reliance on partnership-based revenues and the inherent risks of drug development. Opportunities lie in expanding its pipeline and harnessing emerging technologies, whereas threats include intense competition and regulatory hurdles.

In sum, XOMA Corporation is navigating a complex but rewarding landscape. With a clear mission, a strategic approach to revenue generation, and an awareness of its competitive environment and internal capabilities, XOMA is poised to continue making significant strides in the biopharmaceutical sector. As the company moves forward, its ability to innovate and adapt will be crucial in maintaining its edge and fulfilling its mission of transforming patient lives.

What are the 5 elements of SWOT analysis?

What is a swot analysis in six sigma.

A SWOT analysis is a strategic planning tool used in Six Sigma to assess the strengths, weaknesses, opportunities, and threats of a project or process. This analysis helps Six Sigma practitioners to identify areas for improvement, capitalize on strengths, minimize weaknesses, leverage opportunities, and mitigate threats in order to achieve project success.

What are the four 4 parts of SWOT analysis?

What is a swot analysis for employees.

A SWOT analysis for employees is a strategic planning tool that helps individuals assess their strengths, weaknesses, opportunities, and threats in relation to their job performance and career development.

• Skills and expertise in their field
• Positive work ethic and attitude
• Strong communication and interpersonal skills
• Ability to work well in a team or independently

Weaknesses:

• Areas of skill or knowledge that need improvement
• Lack of experience in certain areas
• Difficulty managing time or prioritizing tasks
• Communication challenges or conflict resolution skills

Opportunities:

• Possibility for career advancement or promotion
• Training or professional development opportunities
• Networking and building relationships within the organization
• Potential for new projects or responsibilities that align with their strengths
• Competition from colleagues for promotions or recognition
• Changes in the industry or company that could impact their role
• Lack of job security or potential for layoffs
• Personal challenges or external factors that could affect their performance

By conducting a SWOT analysis, employees can identify areas for growth and development, set goals for improvement, and leverage their strengths to achieve success in their career.

Want to create a presentation now?

Instantly Create A Deck

Let PitchGrade do this for me

Hassle Free

We will create your text and designs for you. Sit back and relax while we do the work.

Explore More Content

• Privacy Policy
• Terms of Service

© 2023 Pitchgrade

Corporate Governance

Governance at a glance, jack l. wyszomierski.

Jack Wyszomierski has been a director of XOMA since August 2010 and Lead Independent Director since May 2023. From 2004 until his retirement in 2009, Mr. Wyszomierski was Executive Vice President and Chief Financial Officer of VWR International, LLC, a global laboratory supply, equipment and distribution business that serves the world's pharmaceutical and biotechnology companies, as well as industrial and governmental organizations. At Schering-Plough, a global health care company which had worldwide sales of over $8 billion in 2004, Mr. Wyszomierski held positions of increasing responsibility from 1982 to 2004 culminating in his appointment as Executive Vice President and Chief Financial Officer. Mr. Wyszomierski also serves on the Board of Directors of Athersys, Inc., Exelixis, Inc. and SiteOne Landscape Supply, Inc., and previously served on the Board of Directors of Unigene Laboratories, Inc., from 2012 to 2013. He holds an M.S. in Industrial Administration and a B.S. in Administration, Management Science and Economics from Carnegie Mellon University.

Heather L. Franklin

Heather L. Franklin has been a director since August 2021. Ms. Franklin has over 30 years of broad biotechnology expertise. She founded Blaze Bioscience, Inc. in 2011 and has led the company from its infancy to becoming a late clinical stage company. She has served as its Executive Board Chair since January 2024 and served as its President and Chief Executive Officer from 2011 through 2023. Prior to establishing Blaze, Ms. Franklin spent 10 years at ZymoGenetics in positions of increasing responsibility, ultimately serving as senior vice president, business development. She was a member of the executive management team and was responsible for business development including structuring and negotiating in- and out-licenses and collaboration agreements for products at all stages of development from research through commercial. Her other responsibilities included alliance management, strategic planning, portfolio management and pipeline marketing. Earlier in her career, she held roles in program management at Amgen and Targeted Genetics. Ms. Franklin received her M.B.A. from The Wharton School of the University of Pennsylvania, her M.S. from the University of Washington and her B.S. from University of North Carolina at Chapel Hill. Ms. Franklin brings to the Board extensive executive management experience including early to late-stage licensing expertise and financial oversight in the biotechnology industry.

Natasha Hernday

Natasha Hernday has been a director since July 2020. Ms. Hernday was the Chief Business Officer and a member of the Executive Committee for the publicly traded biotechnology company Seagen, Inc., where she worked from 2011 to 2023. She helped execute the sale of Seagen to Pfizer in 2023 and was a member of the executive integration planning team to merge the two oncology businesses. From 1994 through 2010, after starting her career in molecular and mammalian cell biology, Ms. Hernday served in various roles of increasing responsibility at Amgen Inc., including as Director, Mergers & Acquisitions and as Director, Out-Partnering. She serves on the Board for Alpine Immune Sciences, Inc. and on the Knight Campus External Advisory Board for the University of Oregon. Ms.Hernday previously served on the Board of PDL BioPharma, Inc. Ms. Hernday received her BA in microbiology from the University of California at Santa Barbara and M.B.A. from Pepperdine University. Ms. Hernday brings to the Board extensive experience in advising biotechnology companies on matters of leadership, corporate strategy, collaborations and acquisitions.

Owen Hughes

Owen Hughes was appointed full-time Chief Executive Officer in January 2024 after serving as our Executive Chairman of the Board and Interim Chief Executive Officer since January 2023. Mr. Hughes has served as the Chief Executive Officer of Sail Bio, Inc., private biotechnology company focused on addressing toxic proteinopathies, since February 2022 and served as the Chief Executive Officer and co-founder of Cullinan Oncology, Inc., a publicly traded oncology company, from September 2017 to October 2021. Previously, Mr. Hughes served as the Chief Business Officer and Head of Corporate Development at Intarcia Therapeutics, Inc., biotechnology company focused on type II diabetes, from February 2013 to August 2017. Prior to his operating roles, Mr. Hughes spent 16 years on Wall Street in various capacities, including roles at Brookside Capital, an operating division of Bain Capital and Pyramis Global Advisors, a Fidelity Investments Company. Mr. Hughes has served on the Board of Ikena Oncology, Inc., a publicly traded oncology company, since December 2022 and as a member of the Board of Directors of C4 Therapeutics since December 2023. Mr. Hughes served on the Board of Radius Health, Inc., a publicly-traded biopharmaceutical company, from April 2013 to August 2022 until its sale to Gurnet Point Capital and Patient Square Capital; Translate Bio, Inc., a messenger RNA therapeutics company, from July 2016 until its acquisition by Sanofi in September 2021; and FS Development Corp. II, a special purpose acquisition company sponsored by Foresite Capital, from February 2021 to December 2021. Mr. Hughes received a B.A. in History from Dartmouth College. Mr. Hughes has significant experience with biopharmaceutical companies and brings the unique perspective of the Chief Executive Officer of the Company to the Board.

Barbara Kosacz

Barbara Kosacz has been a director since January 2019. From July 2020 until February 2024, Ms. Kosacz served as Chief Operating Officer and General Counsel of Kronos Bio, Inc., where she continues as a strategic advisor. Ms. Kosacz was previously a partner at Cooley LLP since 2002, where she currently serves as a Senior Counsel, and has more than 25 years of experience in counseling clients in the life sciences arena, ranging from early-stage startups to larger public companies, venture funds, investment banks and nonprofit institutions. She serves on the Board of Directors of Athira Pharma, Inc., where she serves as Chair of the compensation committee, and has also served on the Board of Directors of Phoenix Biotech Acquisition Corp., Locus Walk Acquisition Corp., and Arsenal Biosciences, Inc. She also has served as a member of the BIO Emerging Companies’ Section Governing Board, the Board of Trustees of the Keck Graduate Institute, and the advisory board of Locust Walk Partners. Ms. Kosacz has been a speaker at multiple life sciences related conferences, as well as guest lecturer at the University of California, Berkeley School of Law, Stanford University, the University of Pennsylvania and Columbia University on biotechnology law, biotech business models, corporate partnering negotiations and deal structures and bioethics. Recognized by Best Lawyers in America since 2008, Ms. Kosacz and was listed as a “leading lawyer” for healthcare and life sciences in the 2018 Legal 500, as a “Band 1” attorney in the 2018 edition of Chambers USA: America’s Leading Lawyers for Business and recognized as a “highly recommended transactions” lawyer by IAM Patent 1000 for her “nearly three decades advising diverse companies in the industry at a deeply strategic and commercial level and overseeing their most complex and profitable deals.” She received her Juris Doctor degree from the University of California, Berkeley School of Law, and her bachelor’s degree from Stanford University. Ms. Kosacz brings extensive experience in structuring and negotiating strategic combinations and business development transactions and advising biotechnology companies to the Board.

Joseph M. Limber

Joseph M. Limber has been a director since December 2012. Mr. Limber currently serves as President and Chief Executive Officer and a member of the Board of Secura Bio, Inc., a position he has held since February 2019. Prior to that, Mr. Limber served as President and Chief Executive Officer of Genoptix, Inc. from March 2017 through December 2018. Mr. Limber served as Executive Chairman of ImaginAb from January 2016 through November 2017. Mr. Limber served as President and Chief Executive Officer of Gradalis, Inc. from July 2013 through April 2015. Mr. Limber served as President and Chief Executive Officer of Prometheus Laboratories Inc., a subsidiary of Nestlé Health Science, from December 2003 through April 2013 and as a member of its Board from January 2004 through April 2013. From January 2003 to July 2003, Mr. Limber was a consultant and interim Chief Executive Officer for Deltagen, Inc., a provider of drug discovery tools and services to the biopharmaceutical industry. From April 1998 to December 2002, Mr. Limber was the President and Chief Executive Officer of ACLARA BioSciences, Inc. (now Monogram Biosciences, Inc.), a developer of assay technologies and lab-ona-chip systems for life science research. From 1996 to 1998, he was the President and Chief Operating Officer of Praecis Pharmaceuticals, Inc. (acquired by GlaxoSmithKline plc), a biotechnology company focused on the discovery and development of pharmaceutical products. Prior to Praecis, Mr. Limber served as Executive Vice President of SEQUUS Pharmaceuticals, Inc. (acquired by Alza Corporation and now part of the Johnson & Johnson family of companies). He also held management positions in marketing and sales with Syntex Corporation (now F. Hoffmann-La Roche Ltd.) and with Ciba-Geigy Corporation (now Novartis AG). Mr. Limber holds a B.A. from Duquesne University. Mr. Limber brings to the Board his experience in successfully developing markets for specialty pharmaceutical products and managing the critical transition from research organization to commercial entity.

Matthew Perry

Matthew Perry has been a director since February 2017. Mr. Perry was the President of Biotechnology Value Fund Partners L.P. (“BVF”) and portfolio manager for the underlying funds managed by the firm. BVF Partners is a private investment partnership that has focused on small cap, value-oriented investment opportunities for more than 20 years. Mr. Perry joined BVF Partners in December 1996 and has been a successful lead investor in dozens of transactions. He has positively influenced corporate direction for numerous biotechnology companies during the course of his career. In January 2016, Mr. Perry was named to CTI BioPharma Corp.’s Board and was a member of its Compensation Committee until the company was sold in June 2023.. Mr. Perry is also a co-founder and director of Nordic Biotech Advisors ApS, a venture capital firm based in Copenhagen, Denmark. He holds a B.S. degree from the Biology Department at the College of William and Mary. Mr. Perry brings extensive management consulting experience and experience investing in biotechnology companies to the Board.

Board of Directors

Meet our Board of Directors and view their bios

Board Committees

View Committee Composition and Committee Charters

Governance Documents

Guidelines, Charters, and other Governance-related documents

• Email Alerts
• RSS News Feed

• Today's news
• Reviews and deals
• Climate change
• 2024 election
• Fall allergies
• Health news
• Mental health
• Sexual health
• Family health
• So mini ways
• Unapologetically
• Buying guides

Entertainment

• How to Watch
• My Portfolio
• Stock Market
• Biden Economy
• Stocks: Most Actives
• Stocks: Gainers
• Stocks: Losers
• Trending Tickers
• World Indices
• US Treasury Bonds
• Top Mutual Funds
• Highest Open Interest
• Highest Implied Volatility
• Stock Comparison
• Advanced Charts
• Currency Converter
• Investment Ideas
• Research Reports
• Basic Materials
• Communication Services
• Consumer Cyclical
• Consumer Defensive
• Financial Services
• Industrials
• Real Estate
• Mutual Funds
• Credit Cards
• Balance transfer cards
• Cash-back cards
• Rewards cards
• Travel cards
• Personal Loans
• Student Loans
• Car Insurance
• Options 101
• Good Buy or Goodbye
• Options Pit
• Yahoo Finance Invest
• EV Deep Dive
• Fantasy football
• Pro Pick 'Em
• College Pick 'Em
• Fantasy baseball
• Fantasy hockey
• Fantasy basketball
• Download the app
• Daily fantasy
• Scores and schedules
• GameChannel
• World Baseball Classic
• Premier League
• CONCACAF League
• Champions League
• Motorsports
• Horse racing
• Newsletters

New on Yahoo

• Privacy Dashboard

Yahoo Finance

Xoma corporation (xoma).

• Previous Close 25.48
• Day's Range 25.80 - 26.50
• 52 Week Range 13.48 - 27.00
• Volume 6,810
• Avg. Volume 19,204
• Market Cap (intraday) 300.416M
• Beta (5Y Monthly) 0.59
• PE Ratio (TTM) --
• EPS (TTM) -4.04
• Earnings Date May 7, 2024 - May 13, 2024
• Forward Dividend & Yield 2.16 (8.24%)
• Ex-Dividend Date Apr 2, 2024
• 1y Target Est --

XOMA Corporation Overview Biotechnology / Healthcare

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Full Time Employees

December 31

Fiscal Year Ends

Biotechnology

Recent News: XOMA

XOMA (NASDAQ:XOMA) shareholders have earned a 16% CAGR over the last five years

XOMA Corporation Announces Closing of Tender Offer

XOMA Declares Quarterly Preferred Stock Dividends

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

XOMA Corp (XOMA) Reports Mixed Financial Results for Q4 and Full Year 2023

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

XOMA to Present at Upcoming Investor Conferences in March

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

With 37% ownership, XOMA Corporation (NASDAQ:XOMA) has piqued the interest of institutional investors

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

Performance overview: xoma.

Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is S&P 500 .

1-Year Return

3-year return, 5-year return, compare to: xoma.

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: XOMA

Valuation measures.

Enterprise Value

Trailing P/E

Forward P/E

PEG Ratio (5yr expected)

Price/Sales (ttm)

Price/Book (mrq)

Enterprise Value/Revenue

Enterprise Value/EBITDA

Financial Highlights

Profitability and income statement.

Profit Margin

Return on Assets (ttm)

Return on Equity (ttm)

Revenue (ttm)

Net Income Avi to Common (ttm)

Diluted EPS (ttm)

Balance Sheet and Cash Flow

Total Cash (mrq)

Total Debt/Equity (mrq)

Levered Free Cash Flow (ttm)

Research Analysis: XOMA

Analyst recommendations.

• Underperform

People Also Watch

• SUGGESTED TOPICS
• The Magazine
• Newsletters
• Managing Yourself
• Managing Teams
• Work-life Balance
• The Big Idea
• Data & Visuals
• Reading Lists
• Case Selections
• HBR Learning
• Topic Feeds
• Account Settings
• Email Preferences

How to Make a “Good” Presentation “Great”

• Guy Kawasaki

Remember: Less is more.

A strong presentation is so much more than information pasted onto a series of slides with fancy backgrounds. Whether you’re pitching an idea, reporting market research, or sharing something else, a great presentation can give you a competitive advantage, and be a powerful tool when aiming to persuade, educate, or inspire others. Here are some unique elements that make a presentation stand out.

• Fonts: Sans Serif fonts such as Helvetica or Arial are preferred for their clean lines, which make them easy to digest at various sizes and distances. Limit the number of font styles to two: one for headings and another for body text, to avoid visual confusion or distractions.
• Colors: Colors can evoke emotions and highlight critical points, but their overuse can lead to a cluttered and confusing presentation. A limited palette of two to three main colors, complemented by a simple background, can help you draw attention to key elements without overwhelming the audience.
• Pictures: Pictures can communicate complex ideas quickly and memorably but choosing the right images is key. Images or pictures should be big (perhaps 20-25% of the page), bold, and have a clear purpose that complements the slide’s text.
• Layout: Don’t overcrowd your slides with too much information. When in doubt, adhere to the principle of simplicity, and aim for a clean and uncluttered layout with plenty of white space around text and images. Think phrases and bullets, not sentences.

As an intern or early career professional, chances are that you’ll be tasked with making or giving a presentation in the near future. Whether you’re pitching an idea, reporting market research, or sharing something else, a great presentation can give you a competitive advantage, and be a powerful tool when aiming to persuade, educate, or inspire others.

• Guy Kawasaki is the chief evangelist at Canva and was the former chief evangelist at Apple. Guy is the author of 16 books including Think Remarkable : 9 Paths to Transform Your Life and Make a Difference.

Partner Center

View, manage, and install add-ins for Excel, PowerPoint, and Word

When you enable an add-in, it adds custom commands and new features to Microsoft 365 programs that help increase your productivity. Because add-ins can be used by attackers to do harm to your computer, you can use add-in security settings to help protect yourself.

Note:  This article only applies to Microsoft 365 applications running on Windows.

View installed add-ins

You can directly install add-ins from this page or select  More Add-ins  to explore.

In the Office Add-ins dialog, select  My Add-ins  tab.

Select an add-in you want to view the details for and right-click to select  Add-in details  option.

Click a heading below for more information .  

Add-in categories explained

Active Application Add-ins      Add-ins registered and currently running on your Microsoft 365 program.

Inactive Application Add-ins      These are present on your computer but not currently loaded. For example, XML schemas are active when the document that refers to them is open. Another example is the COM add-in: if a COM add-in is selected, the add-in is active. If the check box is cleared, the add-in is inactive.

Document Related Add-ins      Template files referred to by open documents.

Disabled Application Add-ins     These add-ins are automatically disabled because they are causing Microsoft 365 programs to crash.

Add-in      The title of the add-in.

Publisher      The software developer or organization responsible for creating the add-in.

Compatibility      Look here for any compatibility issues.

Location      This file path indicates where the add-in is installed on your computer.

Description This text explains the add-in function.

Note:  Microsoft Outlook has one add-in option in the Trust Center: Apply macro security settings to installed add-ins . InfoPath has no security settings for add-ins.

Permanently disable or remove an add-in

To disable or remove an add-in follow these steps:

Select  File > Get Add-ins . Alternatively, you can select  Home > Add-ins .

In the Office Add-ins dialog, select  My Add-ins  tab.

Select an add-in you want to remove and right click to select  Remove  option.

View or change add-in settings

You can see and change add-in settings in the Trust Center, descriptions of which are in the following section. Add-in security settings may have been determined by your organization so not all options may be available to change.

Select  File  >  Get Add-ins .

Select  More Add-ins > Manage My Add-ins.

Select  Trust Center  >  Trust Center Settings  >  Add-ins.

Check or uncheck the boxes you want.

Add-in settings explained

Require Application Add-ins to be signed by Trusted Publisher      Check this box to have the Trust Center check that the add-in uses a publisher's trusted signature. If the publisher's signature hasn’t been trusted, the Microsoft 365 program doesn’t load the add-in, and the Trust Bar displays a notification that the add-in has been disabled.

Disable notification for unsigned add-ins (code will remain disabled)      When you check the Require Application Extensions to be signed by Trusted Publisher box, this option is no longer grayed out. Add-ins signed by a trusted publisher are enabled, but unsigned add-ins are disabled.

Disable all Application Add-ins (may impair functionality)      Check this box if you don't trust any add-ins. All add-ins are disabled without any notification, and the other add-in boxes are grayed out.

Note:  This setting takes effect after you exit and restart your Microsoft 365 program.

While working with add-ins, you may need to learn more about digital signatures and certificates , which authenticate an add-in, and trusted publishers , the software developers who often create add-ins.

Manage and install add-ins

Use the following instruction to manage and install add-ins.

To install a new add-in:

You can directly install popular add-ins on the page or go to More Add-ins  to explore. 

Select the add-in and select  Add . Or browse by selecting  Store  tab in the Office add-in dialog to find other add-ins to install and select Add for that add-in.

To manage your add-ins:

Select  File > Get Add-ins and from the bottom, select More Add-ins.  Or select  Home  >  Add-ins > More add-ins.

In the Office dialog, select My Add-ins tab. If you are not able to see your add-ins, select  Refresh to reload your add-ins.

Select  Manage My Add-in  to manage and select  Upload to browse and add an add-in from your device.

How to cancel a purchased add-in

If you've subscribed to an add-in through the Microsoft 365 Store that you don't want to continue, you can cancel that subscription.

Open the Microsoft 365 application and go to the Home  tab of the ribbon.

Select  Add-ins  and then select  More Add-ins > My Add-ins tab   to view your existing add-ins.

Select the app you want to cancel and select  Manage My Add-ins .

Under the Payment and Billing section choose Cancel Subscription .

Select  OK and then Continue .

Once that's complete you should see a message that says "You have cancelled your app subscription" in the comments field of your apps list.

Why is my add-in crashing?

Some add-ins might not be compatible with your organization's IT department policies. If that is the case with add-ins recently installed on your Microsoft 365 program, Data Execution Prevention (DEP) will disable the add-in and the program might crash.

Learn more about DEP

Get a Microsoft 365 Add-in for Outlook

Get a Microsoft 365 Add-in for Project

Taking linked notes

If you're looking for Help on linking notes in OneNote to a Word or PowerPoint document, see Take linked notes .

Excel Windows Add-ins

If you're looking for Help on specific Excel Add-ins, such as Solver or Inquire, see Help for Excel for Windows add-ins .

If you're looking for additional help with Excel add-ins using the COM Add-ins dialog box, see Add or remove add-ins in Excel .

Get a Microsoft 365 Add-in for Excel

Need more help?

Want more options.

Explore subscription benefits, browse training courses, learn how to secure your device, and more.

Microsoft 365 subscription benefits

Microsoft 365 training

Microsoft security

Accessibility center

Communities help you ask and answer questions, give feedback, and hear from experts with rich knowledge.

Ask the Microsoft Community

Microsoft Tech Community

Windows Insiders

Microsoft 365 Insiders

Find solutions to common problems or get help from a support agent.

Online support

Was this information helpful?

Thank you for your feedback.

Moscow,10-11 September 2012

Mar 28, 2019

80 likes | 180 Views

Professional social networks as a resource for innovation Svetlana Maltseva Head of IT Innovation and Business Department, HSE. FOCUS GROUP - BRIDGING THE GAP: FROM INNOVATION TO STANDARDS. Moscow,10-11 September 2012. L andscape.

Share Presentation

• vast majority
• european research
• particular research topic
• sized research projects co

September 10, 2012

Home and Community Based Services Cost Report Preparation Training Presented by P&N on behalf of DHH. September 10, 2012. Agenda. Objectives Background Overview of Cost Report Required Attachments to the Cost Report Basic Cost Principles. Objectives.

649 views • 51 slides

Expert meeting on the commercialization of marine biotechnology. 11/10/2012. Portugal Ventures. 600 M€ Invested. 50 Employees. 140 M€ Available. 26 Funds. >150 Portfolio Comp . 2. Investment Focus.

162 views • 0 slides

September 10 th 2012

September 10 th 2012. Introductions. Jake Larkin.71 President, Westerville Ohio, Junior, ME Yuhao Wu.1349 VP/Webmaster, China, Junior, Finance Alex Gerlaugh.2 Treasurer, Worthington Ohio, Sophomore, Accounting Nick Ramstetter.5

392 views • 23 slides

MOSCOW, SEPTEMBER 2011

RUSSIAN INNOVATION STRATEGY - 2020. MOSCOW, SEPTEMBER 2011. INNOVATION: RUSSIA AT THE CROSSROADS. RUSSIA’S STRATEGIC GOALS. INNOVATION-DRIVEN SOCIETY-ORIENTED DEVELOPMENT. Increasing prosperity of Russian citizens. Securing Russia’s role as one of the global leaders.

329 views • 19 slides

September 10, 2012 . Bell Ringer: ACT Prep with clickers!!!!. Flashback- A Long Way Gone Chapters 1-4. During Ishmael’s childhood, he lives in….. New York Liberia Sierra Leone Freeport The sentence “We didn’t know that we were leaving home, never to return is an example of…. imagery

204 views • 7 slides

September 10, 2012. Reminders: Read chapters 5 and 6 for Wednesday. Objective: Sept. 10. Students will understand the basic history and culture of Afghanistan and analyze the friendship between Amir and Hassan in The Kite Runner by : Writing a journal entry

607 views • 52 slides

Scope of Services and Deliverables Presentation PPSD School Board Meeting . September 10, 2012. Presented by: Dr. Sheri L. Miller-Williams, Executive Director. Presentation Outcomes.

326 views • 20 slides

September 11, 2012

September 11, 2012 . Bell Ringer: ACT Prep with clickers!!!!. Chapter 5. List at least 3 different conflicts in this section For each conflict explain: The source of the conflict The nature of the conflict The complications that might influence how the conflict will be resolved Discuss:

127 views • 5 slides

September 11, 2012 Standard: SAP1d-Relate cellular metabolism and transport to homeostasis and cellular reproduction. Warm-Up: Complete ARG 5.1 located on your desk. Read the paragraphs and answer the questions. Write the answers only in your composition notebooks. MEMBRANE TRANSPORT.

309 views • 23 slides

Monday, September 10, 2012

Monday, September 10, 2012. Purpose of H-W Principle:. The Hardy-Weinberg Principle provides a baseline for comparison & determines whether or not gene frequencies have changed in a population and thus whether (micro)evolution has occurred. Hardy-Weinberg Assumptions.

224 views • 13 slides

September 11, 2012. Journal Write the following: 1 sentence in active voice 1 sentence in passive voice Quote “ All great achievements require time.” –Maya Angelou Word of the Day When people talk while Miss Salisbury is trying to get through the lesson, it makes her very peevish .

332 views • 25 slides

September 10 th , 2012

Materials One set of documents, One set of marking the text In notes, write down the objectives, and mark your homework! Objective: To finish the milestones of the Revolution, and practice of reading strategy #1 Homework: 2.1-2.3 (pg. 15-17 ) . September 10 th , 2012 .

266 views • 19 slides

What do you remember about the enlightenment?. September 11, 2012. Agenda 1. Drill 2. Enlightenment Intro Video 3. Survey 4. Maybe Gallery Walk if there is time. . There is a trend in studying the enlightenment that I hope you get from the video. Enlightenment Video.

371 views • 32 slides

Obstructive Sleep Apnea (OSA) Impacting Workplace Safety and Cost. September 11, 2012. Mike Hummel Watermark Medical. “Adequate sleep, like adequate nutrition and adequate exercise, is required for good health”.

434 views • 29 slides

September 10, 2012. In Agenda write: 1) Helping Verbs 2) Alliteration/Assonance Homework: Read for AR 4) Honors Homework: Hyperbole page 4. Helping Verbs. A Helping Verb helps the main verb express action or show time. They are combined with the main verbs to form verb phrases.

252 views • 12 slides

Management roadshow Moscow 10 September 2009

With assistance of. North-West MRSK Corporate Presentation. Management roadshow Moscow 10 September 2009.

343 views • 21 slides

Environmental and Energy Law Resource Teleseminar California GHG Auction: Lessons Learned from EU-ETS. September 11, 2012. INTRODUCTION. Lawrence A. Demase 412-288-4050 [email protected]. I. INTRODUCTION OF SPEAKERS.

595 views • 48 slides

MOSCOW, 2012

EFFECTS OF LONG-TERM WEAK ELECTROMAGNETIC SHIELDING IN INVERTEBRATES. Temuryants N.A. , Kostyuk A.S. , Tumanyants K.N. , Yarmolyuk N.S., Demtsun N.A. Taurida V.I. Vernadsky National University , Simferopol, Crimea, Ukraine. MOSCOW, 2012. Goal of the project:.

226 views • 11 slides

September 10-11, 2007

CRaTER Pre-Environmental Review (I-PER) Calibration Test Planning Justin C Kasper Smithsonian Astrophysical Observatory. September 10-11, 2007. Outline. Objective of CRaTER calibration Relate the ADU of the Pulse Height Analysis to the original energy deposited for each detector

496 views • 42 slides

September 10. 2012

September 10. 2012. Come in and turn your Green “Monkey’s Paw” packet into your class tray. Journal: Compare the weekend to the school week. List at least 3 similarities. You have a quiz today over Monkey’s Paw Get a piece of paper out and put your heading on it.

307 views • 17 slides

91 views • 8 slides

CRaTER Pre-Environmental Review (I-PER) Science Requirements Update Justin C Kasper Smithsonian Astrophysical Observatory. September 10-11, 2007. Outline. Instrument Overview Verification Methods Science Requirements Flowdown Level 1 Requirements in ESMD-RLEP-0010

394 views • 39 slides

• Phone: +90 (212) 875 19 08
• E-Mail: [email protected]

• Company Profile
• Company Policy
• Mission and Vision
• Certificates
• Aluminium Windows
• Aluminium Doors
• Aluminium Sliding Elements
• Aluminium Curtain Walls
• Aluminium Skylight Elements
• Aluminium Frames for Safety and Security
• Aluminium Conservatories
• Metal Panel Sheet Claddings
• Aluminium Entrance Frames
• Glass Structures
• Complementary Items
• Lightweight Steel Structures
• Human Resources OPEN

First successful projects, then lasting relationships!

As it has been in the past 40 years, Mimsa believe in providing competitive prices without compromising their principles of quality. We have managed to create lasting relationships based on honesty and cooperation while adding new customers each year.

Nothing is more important for us than Customer satisfaction!

Mimsa prioritizes customer satisfaction in the services they provide, and strives to understand the customers’ requests thoroughly in order to fulfil their needs and expectations. According to Mimsa Aluminium, every single customer should always be provided with the quality and services above expectations.

Every single completed project is the beginning of a lasting relationship for us.

Mimsa executes every project with experience and knowledge, while continuously improving itself and its high-quality production. Therefore, Mimsa never regards a project as a completed business. Every single project is a successful representation of lasting relationships. Thus, Mimsa pay great attention to post-sale support and keep on supplying uninterrupted support to their customers after completion.

It is very important for us that every single project we execute creates value to our workers, community and environment!

Aiming to create value for the community, environment and humankind in each project. Mimsa perceive that the occupational training of its employees and the new entrants to the workforce gets these individuals well equipped for the industry and community, and so does whatever needed without second thoughts.